Valuation : Rigel Pharmaceuticals, Inc.

Market Cap 868M 745M 699M 639M 1.21B 82.81B 1.21B 8.28B 3.21B 41.78B 3.26B 3.19B 138B P/E 2026 *
14.8x
P/E 2027 * 11.9x
Enterprise Value 868M 745M 699M 639M 1.21B 82.81B 1.21B 8.28B 3.21B 41.78B 3.26B 3.19B 138B EV / Sales 2026 *
2.84x
EV / Sales 2027 * 2.33x
Free-Float
96.65%
Yield 2026 *
-
Yield 2027 * -
1 day-0.22%
1 week+2.67%
Current month+26.22%
1 month+24.26%
3 months+57.60%
6 months+33.74%
Current year+8.48%
1 week 44.5
Extreme 44.505
47.46
1 month 36.14
Extreme 36.14
47.46
Current year 24.95
Extreme 24.95
49.1
1 year 24.95
Extreme 24.95
52.24
3 years 7.12
Extreme 7.12
52.24
5 years 6.4
Extreme 6.4
52.24
10 years 6.4
Extreme 6.4
55
Manager TitleAgeSince
Chief Executive Officer 65 21/11/2014
Director of Finance/CFO 63 29/05/2018
Compliance Officer 58 01/12/2022
Director TitleAgeSince
Director/Board Member 71 01/03/1997
Director/Board Member 65 21/11/2014
Chairman 67 01/05/2022
Date Insider Type Main position Quantity % Market Cap.
7/8/26 A Free

Chief Technology Officer

24,400 0.1319%
5/15/26 A Free

Chairman

5,750 0.0311%
2/20/26 A Fiscal year

Director

12,000 0.0661%
Change 5-day change 1-year change 3-year change Capi.($)
-0.22%+2.67%+16.94%+293.73% 868M
-0.93%-4.46%+61.94%+114.64% 1,060B
-1.14%-0.14%+51.03%+62.52% 651B
-1.42%-0.81%+24.82%+76.15% 465B
-1.07%-2.10%+38.61%+40.46% 365B
-1.77%-0.95%+22.71%+38.34% 300B
-0.74%+1.08%+2.59%+12.74% 258B
+0.11%+1.77%+53.28%+72.05% 238B
-3.18%-0.30%-17.23%-54.33% 210B
+0.46%+3.76%+30.65%+93.20% 184B
Average -0.97%-0.70%+28.54%+74.95% 373.13B
Weighted average by Cap. -1.05%-2.15%+39.31%+67.07%

Financials

2026 *2027 *
Net sales 306M 262M 246M 225M 425M 29.16B 427M 2.91B 1.13B 14.71B 1.15B 1.12B 48.73B 373M 320M 300M 274M 518M 35.56B 520M 3.55B 1.38B 17.94B 1.4B 1.37B 59.42B
Net income 61.66M 52.92M 49.67M 45.37M 85.62M 5.88B 86.03M 588M 228M 2.97B 232M 226M 9.83B 81.45M 69.91M 65.61M 59.93M 113M 7.77B 114M 776M 301M 3.92B 306M 299M 12.98B
Net Debt - -
Logo Rigel Pharmaceuticals, Inc.
Rigel Pharmaceuticals, Inc. is a biotechnology company. The Company is engaged in developing and providing therapies for patients with hematologic disorders and cancer. It focuses on products that address signaling pathways that are critical to disease mechanisms. Its products include TAVALISSE, REZLIDHIA, and GAVRETO. TAVALISSE is an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. REZLIDHIA is used for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation. GAVRETO is a once daily, small molecule, oral, kinase inhibitor of wild type rearranged during transfection (RET) and oncogenic RET fusions. It is used for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory.
Employees
173
Date Price Change Volume
27/08/26 $46.46 -0.04% 44,597
26/08/26 $46.48 -0.58% 232,250
25/08/26 $46.75 +3.64% 373,973
24/08/26 $45.11 -1.70% 542,005
21/08/26 $45.89 +1.41% 322,086
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
46.48USD
Average target price
63.00USD
Spread / Average Target
+35.54%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. RIGL Stock